Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis

V. Balan, E. R. Dickson, R. A. Jorgensen, Keith Lindor

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objective: To study the effects of ursodeoxycholic acid (UDCA) on lipid levels in patients with primary biliary cirrhosis (PBC). Design: A randomized, placebo-controlled prospective trial of UDCA was conducted in 177 well-characterized patients with PBC. Material and Methods: The two treatment groups (placebo and UDCA) were matched at entry with respect to age, sex, histologic stage of PBC, biochemical values, and serum lipid levels. Serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels were measured at entry, 1 year, and 2 years. Results: The decrease in total cholesterol level at 1 and 2 years in the UDCA-treated group was significant in comparison with that in the placebo group. Serum high-density lipoprotein cholesterol and triglyceride levels, however, were unchanged. No severe side effects from UDCA were noted. The changes in serum cholesterol levels at 2 years were directly and strongly correlated with changes in serum bilirubin concentrations (r = 0.70; P<0.001) and inversely correlated with initial serum cholesterol levels (r = -0.86; P<0.00001). Conclusion: The cholesterol- lowering effect of UDCA could be related to amelioration of the underlying liver disease or to a direct effect of the drug on the metabolism of cholesterol in patients with hypercholesterolemia.

Original languageEnglish (US)
Pages (from-to)923-929
Number of pages7
JournalMayo Clinic Proceedings
Volume69
Issue number10
StatePublished - 1994
Externally publishedYes

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Cholesterol
Lipids
Serum
Placebos
HDL Cholesterol
Hypercholesterolemia
Bilirubin
Liver Diseases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. / Balan, V.; Dickson, E. R.; Jorgensen, R. A.; Lindor, Keith.

In: Mayo Clinic Proceedings, Vol. 69, No. 10, 1994, p. 923-929.

Research output: Contribution to journalArticle

Balan, V. ; Dickson, E. R. ; Jorgensen, R. A. ; Lindor, Keith. / Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. In: Mayo Clinic Proceedings. 1994 ; Vol. 69, No. 10. pp. 923-929.
@article{42659e7d4896489fabf24f1f8b8103f7,
title = "Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis",
abstract = "Objective: To study the effects of ursodeoxycholic acid (UDCA) on lipid levels in patients with primary biliary cirrhosis (PBC). Design: A randomized, placebo-controlled prospective trial of UDCA was conducted in 177 well-characterized patients with PBC. Material and Methods: The two treatment groups (placebo and UDCA) were matched at entry with respect to age, sex, histologic stage of PBC, biochemical values, and serum lipid levels. Serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels were measured at entry, 1 year, and 2 years. Results: The decrease in total cholesterol level at 1 and 2 years in the UDCA-treated group was significant in comparison with that in the placebo group. Serum high-density lipoprotein cholesterol and triglyceride levels, however, were unchanged. No severe side effects from UDCA were noted. The changes in serum cholesterol levels at 2 years were directly and strongly correlated with changes in serum bilirubin concentrations (r = 0.70; P<0.001) and inversely correlated with initial serum cholesterol levels (r = -0.86; P<0.00001). Conclusion: The cholesterol- lowering effect of UDCA could be related to amelioration of the underlying liver disease or to a direct effect of the drug on the metabolism of cholesterol in patients with hypercholesterolemia.",
author = "V. Balan and Dickson, {E. R.} and Jorgensen, {R. A.} and Keith Lindor",
year = "1994",
language = "English (US)",
volume = "69",
pages = "923--929",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis

AU - Balan, V.

AU - Dickson, E. R.

AU - Jorgensen, R. A.

AU - Lindor, Keith

PY - 1994

Y1 - 1994

N2 - Objective: To study the effects of ursodeoxycholic acid (UDCA) on lipid levels in patients with primary biliary cirrhosis (PBC). Design: A randomized, placebo-controlled prospective trial of UDCA was conducted in 177 well-characterized patients with PBC. Material and Methods: The two treatment groups (placebo and UDCA) were matched at entry with respect to age, sex, histologic stage of PBC, biochemical values, and serum lipid levels. Serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels were measured at entry, 1 year, and 2 years. Results: The decrease in total cholesterol level at 1 and 2 years in the UDCA-treated group was significant in comparison with that in the placebo group. Serum high-density lipoprotein cholesterol and triglyceride levels, however, were unchanged. No severe side effects from UDCA were noted. The changes in serum cholesterol levels at 2 years were directly and strongly correlated with changes in serum bilirubin concentrations (r = 0.70; P<0.001) and inversely correlated with initial serum cholesterol levels (r = -0.86; P<0.00001). Conclusion: The cholesterol- lowering effect of UDCA could be related to amelioration of the underlying liver disease or to a direct effect of the drug on the metabolism of cholesterol in patients with hypercholesterolemia.

AB - Objective: To study the effects of ursodeoxycholic acid (UDCA) on lipid levels in patients with primary biliary cirrhosis (PBC). Design: A randomized, placebo-controlled prospective trial of UDCA was conducted in 177 well-characterized patients with PBC. Material and Methods: The two treatment groups (placebo and UDCA) were matched at entry with respect to age, sex, histologic stage of PBC, biochemical values, and serum lipid levels. Serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels were measured at entry, 1 year, and 2 years. Results: The decrease in total cholesterol level at 1 and 2 years in the UDCA-treated group was significant in comparison with that in the placebo group. Serum high-density lipoprotein cholesterol and triglyceride levels, however, were unchanged. No severe side effects from UDCA were noted. The changes in serum cholesterol levels at 2 years were directly and strongly correlated with changes in serum bilirubin concentrations (r = 0.70; P<0.001) and inversely correlated with initial serum cholesterol levels (r = -0.86; P<0.00001). Conclusion: The cholesterol- lowering effect of UDCA could be related to amelioration of the underlying liver disease or to a direct effect of the drug on the metabolism of cholesterol in patients with hypercholesterolemia.

UR - http://www.scopus.com/inward/record.url?scp=0028111943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028111943&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 923

EP - 929

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -